{"id":46206,"date":"2015-03-31T09:37:55","date_gmt":"2015-03-31T07:37:55","guid":{"rendered":"http:\/\/www.r-biopharm.com\/?p=46206"},"modified":"2019-08-07T14:58:44","modified_gmt":"2019-08-07T12:58:44","slug":"infliximab-medikamenten-monitoring-verringert-behandlungskosten","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/","title":{"rendered":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1565182669586{margin-bottom: 0px !important;}&#8220;]<strong>Inflixmab (IFX, Remicade\u00ae, Remsima\u00ae, Inflectra\u00ae) Behandlungen k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.<\/strong><\/p>\n<p><!--more--><\/p>\n<p>Patienten, die nicht mehr auf die Behandlung mit Infliximab ansprechen bekommen h\u00e4ufig eine h\u00f6here Dosis des Medikaments.<\/p>\n<p>Steenholdt et al. zeigen in ihrer Studie, dass Therapieanpassung, die auf Medikamenten-Monitoring basiert vergleichbar gute klinische Ergebnisse zeigt, wie die Erh\u00f6hung der Dosis, allerdings zu deutlich geringeren Kosten f\u00fchrt.<\/p>\n<p>Lesen Sie hier das <a href=\"http:\/\/gut.bmj.com\/content\/63\/6\/919.shorttp:\/\/\">Abstract<\/a><strong>.<\/strong><\/p>\n<p>Zusammenfassung der Studien-Ergebnisse:[\/vc_column_text][mk_custom_list style=&#8220;mk-moon-circle-small&#8220;]\n<ul>\n<li>Therapie, die auf Medikamenten-Monitoring (TDM) von Infliximab (IFX) basieren, zeigen vergleichbare klinische Ergebnisse wie solche, bei denen die Dosis erh\u00f6ht wurde.<\/li>\n<li>Die Infliximab-Behandlungskosten werden deutlich reduziert, wenn die Therapie auf Basis von TDM erfolgt.<\/li>\n<li>Die Pharmakokinetik ist h\u00e4ufiger f\u00fcr das Infliximab-Therapieversagen verantwortlich als Medikamenten-Immunogenit\u00e4t.<\/li>\n<\/ul>\n[\/mk_custom_list][vc_column_text css=&#8220;.vc_custom_1565182658605{margin-bottom: 0px !important;}&#8220;]\n<h3>Medikamentenmonitoring von Infliximab &amp; Biosimilars<\/h3>\n<p>Infliximab wird f\u00fcr die Behandlung von entz\u00fcndlichen Erkrankungen wie z. B. Morbus Crohn und Colitis ulcerosa\u00a0 eingesetzt. Aufgrund individueller Pharmakokinetik zeigen unterschiedliche Personen bei identischer Dosierung unterschiedliche IFX-Medikamentenspiegel.<\/p>\n<p>Durch therapeutisches\u00a0 Medikamenten-Monitoring (TDM) kann die Dosierung optimal auf die Bed\u00fcrfnisse des Patienten eingestellt werden. Hierzu wird jeweils vor der n\u00e4chsten Infusion die IFX-Medikamentenkonzentration im Blut gemessen.<\/p>\n<h3>Infliximab Medikamentenmonitoring mit RIDASCREEN<span class=\"regs\">\u00ae<\/span> IFX Monitoring<\/h3>\n<p>RIDASCREEN<span class=\"regs\">\u00ae<\/span> IFX Monitoring ist die kommerzialisierte CE-registrierte Version des home-brew Assays der KU Leuven, die weltweit f\u00fchrend im Bereich des therapeutischen Medikamenten-Monitorings ist. <a href=\"http:\/\/www.r-biopharm.com\/de\/produkte\/klinische-diagnostik\/gastroenterologie\/entzuendliche-darmerkrankungen\/item\/ridascreen-ifx-monitoring\">Produktseite ansehen<\/a><\/p>\n<h3>IFX Biosimilars &#8211; Remsima<span class=\"regs\">\u00ae<\/span> &amp; Inflectra<span class=\"regs\">\u00ae<\/span><\/h3>\n<p>RIDASCREEN<span class=\"regs\">\u00ae<\/span> IFX Monitoring kann nachweislich auch f\u00fcr das Medikamenten-Monitoring der Infliximab Biosimilars Remsima<span class=\"regs\">\u00ae<\/span> und Inflectra<span class=\"regs\">\u00ae eingesetzt werden.<br \/>\n<\/span><\/p>\n<p>Erfahren Sie hier mehr \u00fcber die <a href=\"https:\/\/www.ecco-ibd.eu\/index.php\/publications\/congress-abstract-s\/abstracts-2015\/item\/p040-the-biosimilars-of-infliximab-are-equally-well-quantified-in-a-clinically-validated-infliximab-assay.html\">Studie<\/a><strong>.<\/strong>[\/vc_column_text][vc_cta h2=&#8220;Fragen?&#8220; shape=&#8220;square&#8220; style=&#8220;flat&#8220; add_button=&#8220;right&#8220; btn_title=&#8220;Kontakt&#8220; btn_style=&#8220;flat&#8220; btn_shape=&#8220;square&#8220; btn_color=&#8220;inverse&#8220; btn_link=&#8220;url:mailto%3Aifx%40r-biopharm.de|||&#8220;]Interessiert an weiteren Informationen zum Thema Medikamentenmonitoring? Bitte wenden Sie sich an unsere Produktexperten.[\/vc_cta][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8220;.vc_custom_1565182669586{margin-bottom: 0px !important;}&#8220;]Inflixmab (IFX, Remicade\u00ae, Remsima\u00ae, Inflectra\u00ae) Behandlungen k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.<\/p>\n","protected":false},"author":324,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[255,239,252],"tags":[130,142,198],"class_list":["post-46206","post","type-post","status-publish","format-standard","hentry","category-elisa-de","category-gastroenterologie","category-therapeutisches-drug-monitoring","tag-drug-monitoring","tag-ifx","tag-tdm"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics<\/title>\n<meta name=\"description\" content=\"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics\" \/>\n<meta property=\"og:description\" content=\"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-31T07:37:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-08-07T12:58:44+00:00\" \/>\n<meta name=\"author\" content=\"aschlereth\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"aschlereth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\"},\"author\":{\"name\":\"aschlereth\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"headline\":\"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten\",\"datePublished\":\"2015-03-31T07:37:55+00:00\",\"dateModified\":\"2019-08-07T12:58:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\"},\"wordCount\":343,\"keywords\":[\"drug monitoring\",\"IFX\",\"TDM\"],\"articleSection\":[\"ELISA\",\"Gastroenterologie\",\"Therapeutisches Drug Monitoring\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\",\"url\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\",\"name\":\"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\"},\"datePublished\":\"2015-03-31T07:37:55+00:00\",\"dateModified\":\"2019-08-07T12:58:44+00:00\",\"author\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"description\":\"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.\",\"breadcrumb\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/clinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\",\"url\":\"https:\/\/clinical.r-biopharm.com\/fr\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\",\"name\":\"aschlereth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"caption\":\"aschlereth\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics","description":"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/","og_locale":"de_DE","og_type":"article","og_title":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics","og_description":"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/","og_site_name":"Clinical Diagnostics","article_published_time":"2015-03-31T07:37:55+00:00","article_modified_time":"2019-08-07T12:58:44+00:00","author":"aschlereth","twitter_misc":{"Verfasst von":"aschlereth","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/"},"author":{"name":"aschlereth","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"headline":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten","datePublished":"2015-03-31T07:37:55+00:00","dateModified":"2019-08-07T12:58:44+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/"},"wordCount":343,"keywords":["drug monitoring","IFX","TDM"],"articleSection":["ELISA","Gastroenterologie","Therapeutisches Drug Monitoring"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/","name":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten (de) - Clinical Diagnostics","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"datePublished":"2015-03-31T07:37:55+00:00","dateModified":"2019-08-07T12:58:44+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"description":"Inflixmab (IFX) Behandlungskosten k\u00f6nnen durch therapeutisches Medikamenten-Monitoring (TDM) reduziert werden, bei vergleichbar positiven klinischen Ergebnissen.","breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/infliximab-medikamenten-monitoring-verringert-behandlungskosten\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Infliximab: Medikamenten-Monitoring verringert Behandlungskosten"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed","name":"aschlereth","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","caption":"aschlereth"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/46206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/324"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=46206"}],"version-history":[{"count":3,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/46206\/revisions"}],"predecessor-version":[{"id":98760,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/46206\/revisions\/98760"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=46206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=46206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=46206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}